Iconovo AB

Equities

ICO

SE0010868943

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm Other stock markets 06:54:44 2024-04-30 am EDT			5-day change	1st Jan Change
8.1 ^SEK	+1.50%		+1.25%	-29.87%

Apr. 25	Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 11	Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone	CI

Iconovo Q4 - Aligned with our expectations and a directed issue announcement

February 19, 2024 at 02:10 am EST

Redeye provides an update in relation to Iconovo’s Q4 2023 report. The report did not include any major surprises and aligned with our expectations. However, the company announced a directed issue of SEK33.3m. We argue the directed issue is solid and was better than our estimate. As a result, it positively affects our fair value range, with a new base case of SEK24 (23).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about Iconovo AB

Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone	Mar. 11	CI
Iconovo AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Iconovo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Iconovo AB Signs Additional Contract with Kiox Pharma for the Development of A New Inhalable Treatment for Interstitial Lung Disease	Feb. 07	CI
Iconovo AB Launches Improved Versions of Nasal ICOone Inhalers	Feb. 06	CI
Iconovo Receives Order from Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler	Feb. 01	CI
Arcede Pharma and Iconovo AB Takes the Next Step in the Development of a New Treatment for COPD	Nov. 16	CI
Iconovo AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27	CI
Iconovo AB Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone	23-09-26	CI
Iconovo AB Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations	23-09-19	CI
Iconovo AB Launches Outreach Phase in Structured Process for Out-Licensing of ICOpre	23-09-13	CI
Iconovo AB Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027	23-08-23	CI
Iconovo to Launch Pharmacokinetic Study for Inhalable Treatment Under Kiox Pharma Partnership	23-08-17	MT
Iconovo AB Receives Additional Development Contract from Kiox Pharma for New Inhalable Treatment Against Rare Disease	23-08-17	CI
Iconovo AB, Provides Earnings Guidance for 2024 and 2025	23-08-16	CI
Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-14	CI
Iconovo Increases Sales Efforts and Supply Chain Security for ICOcap Through Restructured Agreement with Stevanato	23-07-13	CI
Iconovo Initiates Collaboration with Affilogic	23-06-22	CI
Sweden's Iconovo to Conduct Feasibility Study on New Treatment of Rare Disease	23-06-09	MT
Iconovo AB Strengthens its Customer Offering in the Novel Pharmaceuticals Business Segment	23-06-01	CI
Iconovo AB Announces Appoints Carl Lindgren as Chief Business Development Officer	23-05-23	CI
Iconovo Taps Investment Bank for Out-licensing of Proprietary Inhaler	23-05-22	MT
Iconovo AB Engages the Global Investment Bank Stifel to Lead A Structured Process to Out-License Its Proprietary Pre-Filled Inhaler ICOpre	23-05-22	CI
Iconovo AB Oxytocin Treatment in Clinical Phase I Study	23-05-15	CI

Chart Iconovo AB

Duration

Period

More charts

Company Profile

Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Companyâs device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Iconovo AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Supplies

	1st Jan change	Capi.
ICONOVO AB	-29.87%	8.67M
COLOPLAST A/S	+9.66%	27.27B
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-29.83%	3.12B
WINNER MEDICAL CO., LTD.	-15.97%	2.53B
INTCO MEDICAL TECHNOLOGY CO., LTD.	+18.11%	2.47B
HARTALEGA HOLDINGS	+3.70%	2B
HARBIN FUERJIA TECHNOLOGY CO., LTD.	-9.47%	1.91B
TOP GLOVE CORPORATION BHD.	-2.22%	1.48B
NAKANISHI INC.	+2.78%	1.3B
KOSSAN RUBBER INDUSTRIES	+18.92%	1.18B

Medical Supplies